Safilens concludes a successful year

Safilens closes this year with excellent results on the plus side. A steadily increasing turnover of +13.2% over 2009 and a wider distribution in Italy, Europe and - last but not least – the United States have made this all-Italian company a jewel in the crown of the ophthalmic sector, thanks to Safilens’ constant investments in research and innovation.
It was precisely the latter that enabled this Fruili-based company to launch the Sage-Gel 7-Days Toric lenses in February 2010, a product offering a uniqueness that has positioned it on the market as an important alternative to lenses currently available for correcting astigmatism. Then, almost contemporarily, the highly innovative nature of the hyaluronic acid-based technology finally received international acceptance thanks to the approval of the American FDA, the government authority on the safety of medical and health care products marketed in the United States.
After a few months, also Safe Gel 1-day lenses (note that the name in USA is “Safigel”) obtained positive feedback in the USA by adapting to the high standards required. Its launch, on July 6, 2010, saw the involvement of some of the most influential American opinion leaders, who enhanced the visibility of the product and shared information on its attributes and characteristics with patients, thereby promoting its use.
Safe gel 1-day lenses guarantee wellness and comfort for all American lens wearers who, thanks to the natural JALURONATE – GEL bio-polymer with hyaluronic acid, can maintain and restore the pseudo-mucinic volume of the lachrymal film, ensuring constant and unaltered lachrymation while also guaranteeing a balanced supply of oxygen.
“We are truly proud of this highly successful year,” declared Fernando Garbellotto, President of Safilens. “We worked hard and invested in research and innovation to reach these goals. Given these excellent initial sales figures in the United States, we hope to become the leader overseas as well.”
Enthusiasm and optimism: key elements that lead to the success of this Italian company and drive it towards a 2011 brimming with good news.
The next year will see Safilens more intensely committed than ever to research, in particular in relation to its collaboration with universities. In this way, it will be able to produce and launch products that are increasingly innovative and on the cutting edge. Alessandro Filippo, Head of R&D for Safilens emphasizes that “Research on hyaluronic-acid contact lenses today is a highly interesting and cutting-edge issue on the forefront of the international scene, having a positive impact on the daily use of contact lenses. This is an enormous opportunity that Safilens, a highly innovative company, has succeeded in grasping and developing with considerable far-sightedness. For us, 2011 will be a key year for confirming our professionalism on the market and offering our customers a high-quality product that guarantees absolute comfort and wellness.”